Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 9Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 7Glioblastoma 7Colorectal Neoplasms 6Gliosarcoma 5Neoplasm Metastasis 4Colonic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Rectal Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solitary Fibrous Tumor, Pleural 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Mesothelioma, Malignant 2Melanoma 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Astrocytoma 2Waldenstrom Macroglobulinemia 1

Interventions

aldesleukin 26Sunitinib 25Interferon-alpha 21Everolimus 18Sorafenib 16Cyclophosphamide 16Filgrastim 13Bevacizumab 13Nivolumab 11Gemcitabine 11Interleukin-2 10Axitinib 10fludarabine phosphate 9Gene Expression Profiling 9temsirolimus 8Peripheral Blood Stem Cell Transplantation 8Doxorubicin 8pembrolizumab 7Radiotherapy 6Radiosurgery 6Polymerase Chain Reaction 6Ipilimumab 6Carboplatin 6sargramostim 5Ifosfamide 5Fluorouracil 5Erlotinib Hydrochloride 5Capecitabine 5Bortezomib 5atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Kidney Neoplasms × cediranib × Clear all
NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTINâ„¢) in Metastatic or Recurrent Renal Cell Carcinoma

AstraZeneca

Phase 2 Completed
105 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡